EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
Peakefavirenz; lamivudine; tenofovir disoproxil fumarate
NDAORALTABLETPriority Review
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE (efavirenz; lamivudine; tenofovir disoproxil fumarate) by Hetero is fixed-dose combination of antiviral drugs efv, 3tc, and tdf with antiviral activity against hiv-1 [see ]. First approved in 2019.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing efavirenz, lamivudine, and tenofovir disoproxil fumarate—three antiretroviral agents used to treat HIV-1 infection. The combination works through complementary mechanisms: efavirenz inhibits reverse transcriptase, while lamivudine and tenofovir are nucleoside/nucleotide reverse transcriptase inhibitors. It is administered orally as a single tablet regimen, simplifying patient adherence.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30%), suggesting a stable but contested market position requiring strong commercial execution.
Mechanism of Action
fixed-dose combination of antiviral drugs EFV, 3TC, and TDF with antiviral activity against HIV-1 [see ].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this HIV combination therapy offers exposure to a complex, heavily regulated therapeutic area with strong reimbursement frameworks and deep prescriber relationships. Roles tend to be commercially focused given the product's mature lifecycle, emphasizing sales execution, payer negotiations, and patient retention over development activities.
Brand ManagerRegional Sales Manager
Worked on EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE at Hetero? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.